Weill Cornell Lymphoma Program

Weill Cornell Lymphoma Program Enabling patients with lymphoma to have the best possible clinical outcomes.

The Lymphoma Program at Weill Cornell Medical College/NewYork-Presbyterian Hospital, located on the Upper East Side of New York City, is internationally recognized for our efforts to enable patients with non-Hodgkin’s lymphoma, Hodgkin’s disease and related disorders to have the best possible clinical outcome, including cure when possible. The goal of our page and blog is to provide you with up-to-date information about the latest developments in lymphoma treatment and research.

Listen to Dr. Sarah Rutherford on the OncLive On Air   where she discusses the use of circulating tumor DNA (ctDNA) to h...
12/16/2025

Listen to Dr. Sarah Rutherford on the OncLive On Air where she discusses the use of circulating tumor DNA (ctDNA) to help shape treatment strategies:

Dr Rutherford discusses the use of ctDNA testing for guiding lymphoma management and trials that seek to determine the best use of this type of assay.

  expert Dr. Richard Furman and Dr. Gail Roboz of the Weill Cornell Leukemia Program  joined the Weill Cornell Medicine ...
12/11/2025

expert Dr. Richard Furman and Dr. Gail Roboz of the Weill Cornell Leukemia Program joined the Weill Cornell Medicine podcast to talk about the they were most excited about. Listen here:

Podcast Episode · CancerCast · 12/03/2025 · 1 sec

11/25/2025

At , Dr. John Allan highlighted progress in for frontline chronic lymphocytic leukemia (CLL) doublet and triplet treatment regimens: https://bit.ly/4o3C3pt

Watch Dr. Jia Ruan talk about emerging targeted therapies for peripheral T-cell   in this Oncology Learning Network vide...
11/21/2025

Watch Dr. Jia Ruan talk about emerging targeted therapies for peripheral T-cell in this Oncology Learning Network video from :

Jia Ruan, MD, shares insights into novel targeted therapies for patients with peripheral T-cell lymphoma at the 2025 Lymphoma, Leukemia, & Myeloma Congress.

Dr. Sarah Rutherford’s talk at   on a combination therapy for   was mentioned as one of the most notable conference pres...
11/07/2025

Dr. Sarah Rutherford’s talk at on a combination therapy for was mentioned as one of the most notable conference presentations in this Healio video:

In this video, Leo I. Gordon, MD, FACP, discusses notable presentations from Lymphoma, Leukemia & Myeloma Congress.

10/31/2025

Dr. Sarah Rutherford outlined strategies for treating elderly patients with including how she approaches treatment and the use of combination and regimens: https://bit.ly/47sAife

Watch Dr. Erin Mulvey explain emerging treatments for relapsed/refractory Follicular   at  : https://bit.ly/4nkXMZH (cc:...
10/29/2025

Watch Dr. Erin Mulvey explain emerging treatments for relapsed/refractory Follicular at : https://bit.ly/4nkXMZH (cc: Oncology Learning Network)

Erin Mulvey, MD, discusses novel treatment options for patients with relapsed/refractory follicular lymphoma at the 2025 Lymphoma, Leukemia & Myeloma Congress.

Join Dr. Peter Martin tomorrow 10/22 for a Lymphoma Research Foundation webinar diving into everything you need to know ...
10/21/2025

Join Dr. Peter Martin tomorrow 10/22 for a Lymphoma Research Foundation webinar diving into everything you need to know about Mantle Cell , including symptoms, treatment options, clinical trials, quality of life, and more. Register here: https://bit.ly/3IWj8Pb

Listen to Dr. John Allan speak with OncLive about what factors influence treatment decision-making for patients with chr...
10/10/2025

Listen to Dr. John Allan speak with OncLive about what factors influence treatment decision-making for patients with chronic lymphocytic leukemia ( ):

Allan and Rubianes discuss factors that influence treatment decision-making for patients with chronic lymphocytic leukemia.

Join Dr. Peter Martin on Tuesday, October 7 for a webinar hosted by The Patient Story where he’ll be answering the most ...
10/03/2025

Join Dr. Peter Martin on Tuesday, October 7 for a webinar hosted by The Patient Story where he’ll be answering the most important questions about living with . Register here to hear his expert insights:

Got questions about follicular lymphoma? Dr. Peter Martin answers what matters most to patients in this expert Q&A. Register now to join.

ICYMI: the combination of nivolumab + AVD outperformed a brentuximab vedotin based regimen in older patients with classi...
08/08/2025

ICYMI: the combination of nivolumab + AVD outperformed a brentuximab vedotin based regimen in older patients with classic according to led by Dr. Sarah Rutherford: https://bit.ly/3UHaGW0 (cc: Targeted Oncology)

A recent trial reveals that nivolumab combined with chemotherapy significantly improves survival rates in older patients with advanced Hodgkin lymphoma.

  led by Dr. Sarah Rutherford compared two different combination treatment regimens for advanced classical   patients ov...
08/06/2025

led by Dr. Sarah Rutherford compared two different combination treatment regimens for advanced classical patients over the age of 60:

In a subset analysis from the phase III SWOG S1826 trial reported in the Journal of Clinical Oncology, Rutherford et al compared the survival outcomes of nivolumab plus AVD vs brentuximab vedotin plus...

Address

520 East 70th Street, Starr Pavilion, 3rd Floor
New York, NY
10065

Alerts

Be the first to know and let us send you an email when Weill Cornell Lymphoma Program posts news and promotions. Your email address will not be used for any other purpose, and you can unsubscribe at any time.

Share

Share on Facebook Share on Twitter Share on LinkedIn
Share on Pinterest Share on Reddit Share via Email
Share on WhatsApp Share on Instagram Share on Telegram

Category

Our Story

The Lymphoma Program at Weill Cornell Medicine and NewYork-Presbyterian Hospital is one of the leading clinical and scientific research centers in the world. The renowned experts that comprise our team are committed to delivering compassionate, cutting-edge care to improve the lives of people with lymphoma before, during and for years after treatment.

We are not content to care only for current lymphoma patients; we also actively pursue medical advances that will alleviate the suffering of those affected by the disease in the future. Whether acting as your primary oncologist, working in tandem with your oncologist or primary physician, overseeing your participation in a clinical trial or providing a second opinion, we are pleased to help all patients achieve the best possible results.